	Application N .	Applicant(s)
	-	
Notice of Allowability	09/986,666 Examiner	HO ET AL. Art Unit
	Karen Cochrane Carlson, Ph.D.	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>September 9, 2003</u> .		
2. The allowed claim(s) is/are <u>Claims 20-29, 31, 32, and 36-38</u> .		
3. The drawings filed on are accepted by the Examiner.		
 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 		
 Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
 Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). 		
* Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
(a) The translation of the foreign language provisional application has been received.		
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE		
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No 		
(b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner.		
(c) 🔲 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1 Notice of References Cited (PTO-892)	5☐ Notice of Informal Pa	tent Application (PTO-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948)		PTO-413), Paper No
3⊠ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No. 2 IDSs), 7⊠ Examiner's Amendme	ent/Comment
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8囗 Examiner's Statemen 9❑ Other	t of Reasons for Allowance

This Allowance is in response to the paper filed September 9, 2003. Claims 1-19, 30, and 33-35 have been canceled. Claims 20-29, 31, 32, and 36-38 are currently pending and are under examination.

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mary-Elizabeth Buckles on November 21, 2003.

Examiner's Amendments to the Claims:

Claims 29 and 36 have been scanned into the electronic database and the last line of each claim is not readable. Therefore, these Claims are repeated below:

29. (amended) The composition of Claim 28 wherein said hemoglobin is rHb (βL105W) (SEQ ID NO: 8).

36. (amended) A method of treating a human subject, comprising administering to said subject a nontoxic composition comprising an artificial mutant hemoglobin, wherein said artificial mutant hemoglobin is rHb (βL105W) (SEQ ID NO: 8).

Claim 38 is amended herein as follows:

38. (amended) The hemoglobin of Claim 22 further [posessing] <u>possessing</u> increased stability [agianst] <u>against</u> autooxidation.

Examin r's Am ndm nts to th Sp cification:

Replace Amendment B1 with:

Application/Control Number: 09/986,666

Page 3

Art Unit: 1653

--This application is a divisional application of SN 09/598,216, filed June 21, 2000, now U.S.

Patent 6, 486,123.---

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is (703) 308-0034. The Examiner can normally be reached daily except alternate Fridays from 7:30 A.M. to 5:00 P.M.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Christopher Low, can be reached at (703) 308-2329. The OFFICIAL fax phone number for Technology Center 1600 is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

KAREN COCHRANE CARLSON, PH.D.

Kan Cehrone Carbon Rid